Cingulate logo
Cingulate
CING | NASDAQ
Chart Builder DCF Calculator
$3.75
-$0.55 (-12.79%)
At close: Nov 16, 2026, 4:00 PM ET
$3.71
-$0.04 (-1.07%)
After-hours: Nov 16, 2026, 7:53 PM ET

Cingulate Company Profile

Company profile explained

Company Profile

Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.

Key Executives

Name Position
Shane J. Schaffer Co-Founder, Chief Executive Officer & Chairman of the Board
Downey Bryan Wade Executive VP & Chief Commercial Officer
Jennifer L. Callahan Executive VP, CFO & Secretary
Matthew N. Brams Co-Founder, Executive Vice President & Chief Medical Officer
Raul R. Silva Co-Founder, Executive Vice President & Chief Science Officer
Thomas Dalton Vice President of Investor & Public Relations

Latest SEC Filings

Date Type Title
Oct 02, 2026 4 Filing
Oct 02, 2026 8-K Current Report
Aug 13, 2026 10-Q Quarterly Report
Aug 13, 2026 8-K Current Report
Jul 23, 2026 8-K Current Report
Jul 20, 2026 4 Filing
Jul 20, 2026 4 Filing
Jul 20, 2026 4 Filing
Jul 20, 2026 4 Filing
Jul 20, 2026 4 Filing
View All SEC Filings ➞
Cingulate
Cingulate logo
Country United States
IPO Date Dec 8, 2021
Industry Biotechnology
Sector Healthcare
Employees 14
CEO Shane J. Schaffer

Contact Details

1901 West 47th Place Kansas City, Kansas 66205 United States

Stock Details

Ticker Symbol CING
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001862150
CUSIP Number 17248W303
ISIN Number US17248W3034
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.